Last reviewed · How we verify

Gleevec, RAD001, and Hydroxyurea

Annick Desjardins · Phase 1 active Small molecule Quality 0/100

Gleevec, RAD001, and Hydroxyurea is a Small molecule drug developed by Annick Desjardins. It is currently in Phase 1 development. Also known as: Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameGleevec, RAD001, and Hydroxyurea
Also known asGleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide
SponsorAnnick Desjardins
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gleevec, RAD001, and Hydroxyurea

What is Gleevec, RAD001, and Hydroxyurea?

Gleevec, RAD001, and Hydroxyurea is a Small molecule drug developed by Annick Desjardins.

Who makes Gleevec, RAD001, and Hydroxyurea?

Gleevec, RAD001, and Hydroxyurea is developed by Annick Desjardins (see full Annick Desjardins pipeline at /company/annick-desjardins).

Is Gleevec, RAD001, and Hydroxyurea also known as anything else?

Gleevec, RAD001, and Hydroxyurea is also known as Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide.

What development phase is Gleevec, RAD001, and Hydroxyurea in?

Gleevec, RAD001, and Hydroxyurea is in Phase 1.

Related